Yiwei Li is a Supervisory Pharmaceutical Scientist in the Office of Pharmaceutical Manufacturing Assessment (OPMA), Office of Pharmaceutical Quality (OPQ), at CDER/FDA. He joined the FDA in 2014 and serves as a process and facility assessor, responsible for evaluating manufacturing processes and facilities in support of NDA and ANDA reviews. Prior to joining the FDA, Yiwei had more than 13 years of experience in the pharmaceutical industry, including roles at Merck Research Laboratories and Inception
Sciences. He earned his Ph.D. in Organic Chemistry from The Scripps Research Institute, where his research focused on organic synthesis and natural product total synthesis.